Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Manfidokimab - Akeso Biopharma

Next Previous
X
Search
Drug Profile

Manfidokimab - Akeso Biopharma

Alternative Names: AK-120 - Akeso Biopharma; IL-4R monoclonal antibody

Latest Information Update: 14 Jan 2025

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Akeso Biopharma
  • Class Anti-inflammatories; Antiasthmatics; Antibodies; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Discontinued Asthma; Eosinophilic oesophagitis

Most Recent Events

  • 10 Jan 2025 Akeso plans a phase III trial for Atopic dermatitis (In adolescents) in China (SC, Injection) (NCT06767540)
  • 28 Nov 2024 No recent reports of development identified for phase-I development in Atopic-dermatitis(In the elderly, In adults) in Australia (SC)
  • 13 Nov 2024 Akeso completes a phase II trial in Atopic dermatitis (In adults, In the elderly) in China (SC) (NCT06092762)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top